NEW YORK (GenomeWeb News) – Alere has licensed the worldwide marketing rights to VitaPath Genetics' spina bifida risk assessment assay, the companies announced Wednesday.
The deal also gives Alere the right to develop with Foster City, Calif.-based VitaPath additional product line extensions mainly focusing on fetal health.
Financial and other terms of the deal were not disclosed.
VitaPath's assay is a genetic test that identifies elevated risk in women of childbearing age for spina bifida, which can be prevented with folic acid. The assay is expected to be launched in 2012.
VitaPath is a developing DNA-based tests. It raised $6 million in a Series A financing round in 2009.
Alere, based in Waltham, Mass., develops and manufactures diagnostics products.